As a leading full-service analytical laboratory serving the pharmaceutical industry for more than 30 years, at Neopharm, we are investing in the development of a new facility with state-of-the-art technology to support the growing field of biological products in the healthcare industry.
Read MoreEVAH Corp. (EVAH or the company) has announced the successful completion of a Series B financing round, raising $8.5 million. This additional financing brings EVAH’s total funding since its launch in 2020 to $28.5 million.
A business and development platform in the animal health industry, EVAH specializes in the development of vaccines to prevent bacterial diseases in food animals. The company also designs microbiome solutions for improved growth performance and medicated feed against parasites.
Read MoreIn Canada, one out of twelve people—many of whom are children—has a rare disease. Unfortunately, treatments are only available for a small percentage of these conditions. Even when treatments that might dramatically improve the quality of a patient's life are available, they are often unaffordable and out of reach.
Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy for Drugs for Rare Diseases, with an investment of up to $1.5 billion over three years. Through this, we will help increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada, including children.
Read MoreThe Government of Canada continues to make significant investments to strengthen Canada’s biomanufacturing and life sciences sector. Our approach prioritizes innovative solutions and long-term domestic biomanufacturing capacity right here at home. Since March 2020, over $1.8 billion has been invested across 34 projects to rebuild Canada’s vaccines, therapeutics and biomanufacturing capacity.
Read MoreDiex Research announces the official opening of its Quebec City site since its relocation on September 12, 2022, which is now located at Place de la Cité. Diex Research is a leader in the clinical research industry and is committed to providing superior services to its clients while maintaining the highest standards for safety and ethics.
Read MoreUnder the agreement, Defence will develop the first radio-immuno-conjugate therapy based on an Auger electron emitter by combining Defence’s intracellular targeting and radiochemistry expertise provided by Orano SA, a world-renowned multinational company based in Chatillon, France.
Read MoreAstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.
Read MoreToday, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.
Read MoreCongruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.
Read MoreWe would like to notify you that as of February 17, 2023, Emmanuelle Toussaint no longer holds the position of Executive Director at BIOQuébec. BIOQuébec is very appreciative of the tremendous work done by Emmanuelle and grateful for her dedication and involvement over the past six months. We wish her continued success in her professional journey.
Read MoreThe Governments of Canada and Prince Edward Island today announced funding for a $50 million BioAccelerator, which will be home to CASTL’s (Canadian Alliance for Skills and Training in Life Sciences) headquarters and expanded training facility.
Read MoreAplantex is pleased to announce the composition of the company’s C-suite. "Aplantex is the result of the innovative work of a multidisciplinary team of skilled individuals committed to simplifying and broadening access to the valuable plant-based bioactive molecules that daily impact our health and well-being," states Mr. Charest.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%.
Read MoreAmgen, one of the world’s leading biotechnology companies, and Mila – Quebec Artificial Intelligence Institute, are expanding their partnership aimed at further transforming Artificial Intelligence (AI) guided drug development. As part of this evolution, Amgen is establishing a corporate laboratory within Mila’s headquarters where scientists from both organizations will interact and engage.
Read MoreThe Honourable Pablo Rodriguez, Minister of Canadian Heritage and Quebec Lieutenant, today announced, on behalf of the Honourable Pascale St–Onge, Minister of Sport and Minister responsible for Canada Economic Development for Quebec Regions (CED), a repayable contribution of $600,000 for CIRION BioPharma Research Inc.
Read MoreThe Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced its expansion into Quebec with the location of their future Biomanufacturing Training Facility in Montreal.
Read MoreGiiant Pharma Inc., a Canadian, preclinical-stage biotech company, today announced that the Company will receive financial support from the US Crohn’s and Colitis Foundation, through its IBD Ventures program, for an amount up to US$ 500,000.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.
Read MoreAbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.
Read More
